---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013054"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:19:51.558604+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Capricor Q2 net loss $7.1M; CAP-1002 Phase 3 trial underway, cash $51.4M

## Summary
- Net loss $7.1M ($0.29/share) vs $4.7M ($0.21/share) in Q2 2021.
- Cash & equivalents $51.4M at June 30, 2022, up from $34.9M at Dec. 31, 2021.
- First patient dosed in HOPE-3 pivotal Phase 3 trial of CAP-1002 for late-stage Duchenne muscular dystrophy.
- Positive one-year HOPE-2 OLE data showed statistically significant skeletal muscle improvement (PUL v2.0, p=0.02).
- Requesting FDA meeting to discuss CAP-1002 approval pathway; cash runway into Q2 2024.

## SEC filing metadata
- accession: 0001558370-22-013054
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/0001558370-22-013054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/capr-20220810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013054
- JSON: https://secwatch.observer/filing/0001558370-22-013054.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.